微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 82.15% | 22.52% | 1.56% | 16/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 80.89% | 22.04% | 1.28% | 18/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 79.87% | 32.56% | 16.57% | 18/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 68.51% | 33.84% | 2.19% | 36/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 67.05% | 37.33% | 1.16% | 37/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 66.28% | 47.02% | 10.01% | 40/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 60.25% | 35.97% | 17.7% | 49/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 51.19% | 16.58% | 4.85% | 74/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 48.82% | 10.67% | 8.3% | 82/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 45.08% | 3.54% | 1.74% | 93/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 44.31% | 1.27% | 0.92% | 91/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 43.91% | 22.28% | -0.47% | 93/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 44.12% | 24.02% | 1.32% | 89/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 43.54% | 28.78% | -0.49% | 92/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 43.75% | 18.16% | 21.85% | 87/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 35.91% | -0.15% | 0.95% | 118/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 35.57% | -6.17% | 5.2% | 103/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 33.81% | -7.09% | -8.69% | 115/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 37.03% | 25.88% | 2.96% | 92/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 35.96% | 9.13% | -5.14% | 113/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 37.91% | 4.01% | 4.18% | 94/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 36.39% | 10.65% | 23.71% | 104/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 29.42% | -8.03% | -10.74% | 97/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 32.96% | 3.19% | -9.58% | 113/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 36.45% | -42.4% | 10.83% | 85/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 32.89% | -52.37% | 2.83% | 97/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 31.98% | -53.38% | 0.14% | 91/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 31.94% | -55.26% | -49.53% | 111/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 63.28% | -14.21% | -8.36% | 32/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 69.05% | -5.71% | 0.65% | 23/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 68.61% | -4.31% | -3.9% | 23/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 71.39% | 0.7% | -3.22% | 23/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 73.77% | 2% | 0.72% | 15/159 | 49% | 贝达药业 | 95.81% | 行业排名> |
| 2017-06-30 | 73.24% | 5.64% | 2.15% | 14/159 | 47.74% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 71.7% | 2% | 1.14% | 13/159 | 46.55% | 贝达药业 | 95.58% | 行业排名> |
| 2016-12-31 | 70.89% | 2.6% | 2.25% | 17/159 | 48.19% | 退市金泰 | 95.93% | 行业排名> |
| 2016-06-30 | 69.33% | 2% | 0.34% | 15/159 | 45.89% | 贝达药业 | 95.89% | 行业排名> |
| 2015-12-31 | 69.09% | 6.58% | 6.58% | 14/159 | 45.97% | 微芯生物 | 97.46% | 行业排名> |